Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Acquired by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC increased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 58.5% in the 3rd quarter, HoldingsChannel reports. The fund owned 872 shares of the medical research company’s stock after purchasing an additional 322 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Bio-Rad Laboratories were worth $292,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System boosted its stake in Bio-Rad Laboratories by 341.7% during the third quarter. Louisiana State Employees Retirement System now owns 5,300 shares of the medical research company’s stock worth $1,773,000 after buying an additional 4,100 shares during the period. Ballentine Partners LLC acquired a new position in shares of Bio-Rad Laboratories in the 3rd quarter worth approximately $227,000. Greenleaf Trust purchased a new position in shares of Bio-Rad Laboratories during the 3rd quarter worth approximately $202,000. Raymond James & Associates increased its holdings in Bio-Rad Laboratories by 8.6% in the 3rd quarter. Raymond James & Associates now owns 14,915 shares of the medical research company’s stock valued at $4,990,000 after purchasing an additional 1,179 shares during the last quarter. Finally, Blue Trust Inc. raised its position in Bio-Rad Laboratories by 22.9% in the third quarter. Blue Trust Inc. now owns 1,056 shares of the medical research company’s stock valued at $353,000 after purchasing an additional 197 shares during the period. Institutional investors and hedge funds own 65.24% of the company’s stock.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now directly owns 147 shares of the company’s stock, valued at approximately $48,582.03. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP James Barry sold 623 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the sale, the executive vice president now owns 147 shares of the company’s stock, valued at $48,582.03. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 17.50% of the company’s stock.

Bio-Rad Laboratories Trading Down 0.4 %

BIO opened at $372.77 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. The stock has a market capitalization of $10.39 billion, a price-to-earnings ratio of -13.64 and a beta of 0.93. The business has a fifty day moving average price of $336.19 and a 200 day moving average price of $309.99. Bio-Rad Laboratories, Inc. has a 12 month low of $262.12 and a 12 month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.85. The business had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The business’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.33 earnings per share. Sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 9.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BIO. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price target for the company. StockNews.com upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Citigroup boosted their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, Royal Bank of Canada raised their price objective on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $391.80.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.